A snapshot of licensed biosimilars: January 2017
| Biosimilar | Reference Drug | Company | Approvals | |||||
| S Korea | EU | Canada | Japan | US | India | |||
| CT-P13 (Remsima/Inflectra/Flammegis) | Remicade | Celltrion/Pfizer (Hospira) Nippon Kayaku/Egis | Jul-12 | Sep-13 | Jan-14 | Jul-14 | Apr-16 | -- |
| HD203 (Davictrel)* | Enbrel | Hanwha Chemical | Nov-14 | -- | -- | -- | -- | -- |
| SB4 (Benepali/Brenzys) | Enbrel | Samsung Bioepis | Sep-15 | Jan-16 | Aug-16 | -- | -- | -- |
| SB2 (Flixabi/Renflexis) | Remicade | Samsung Bioepis | Dec-15 | May-16 | -- | -- | -- | -- |
| GP2015 (Erelzi) | Enbrel | Sandoz (Novartis) | -- | -- | -- | -- | Aug-16 | -- |
| ABP 501 (Amjevita) | Humira | Amgen | -- | Jan-17 | -- | -- | Sep-16 | -- |
| CT-P10 (Truxima) | MabThera | Celltrion | -- | Feb-17 | -- | -- | -- | -- |
| ZRC-3197 (Exemptia)† | Humira | Zydus Cadila | -- | -- | -- | -- | -- | Sep-14 |
| BOW015 (Infimab)† | Remicade | Ranbaxy Laboratories | -- | -- | -- | -- | -- | Dec-14 |
| Intacept† | Enbrel | Intas Pharmaceuticals | -- | -- | -- | -- | -- | Mar-15 |
| Adfrar† | Humira | Torrent Pharmaceuticals | -- | -- | -- | -- | -- | Jan-16 |
*Withdrawn from the market Sep-15; †Not following EMA or FDA standards of approval.